US nod for Akcea/Ionis’ Tegsedi
Akcea and Ionis’ Tegsedi has won US approval for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs.
Read More
Tag: Ionis
FDA rejects Akcea/Ionis’ rare disease drug Waylivra
US regulators have rejected Akcea/Ionis’ application to market Waylivra for the ultra-rare rare lipid disorder familial chylomicronemia syndrome (FCS).
Read More
EU approval for Akcea/Ionis’ rare disease therapy
European regulators have approved Akcea and Ionis’ Tegsedi for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs.
Read More
AZ buys Ionis’ NASH candidate
AstraZeneca has bought rights to an experimental antisense therapy from Ionis Pharmaceuticals, in a deal that could be worth more than $300 million
Read More
GSK walks away from Ionis antisense drugs
GlaxoSmithkline has turned down options to take on board Ionis Pharmaceuticals’ experimental antisense therapies inotersen and IONIS-FB-LRx following a pipeline revamp.
Read More
Mixed fortunes continue for Ionis rare disease drug inotersen
Meets its Phase III targets but concerns remain over its side effects profile
Read More
Novartis taps into Ionis’ cardiovascular drugs
Novartis has signed an exclusive option agreement with Ionis and affiliate Akcea to license two investigational therapies that could significantly reduce cardiovascular risk in patients living with elevated levels of lipoproteins Lp(a) and ApoCIII.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
